Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Monday

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) is expected to be announcing its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($0.63) per share for the quarter.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA traded down $0.16 during trading hours on Monday, hitting $4.21. The stock had a trading volume of 1,232,363 shares, compared to its average volume of 1,094,469. Olema Pharmaceuticals has a one year low of $4.18 and a one year high of $16.62. The company has a market cap of $241.22 million, a price-to-earnings ratio of -1.92 and a beta of 2.05. The business's 50 day moving average is $5.54 and its 200-day moving average is $9.10.

Insider Activity at Olema Pharmaceuticals

In other news, insider David C. Myles sold 12,452 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.38, for a total value of $116,799.76. Following the completion of the sale, the insider now owns 611,947 shares of the company's stock, valued at approximately $5,740,062.86. This represents a 1.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were purchased at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the acquisition, the insider now owns 7,800,000 shares of the company's stock, valued at $44,928,000. The trade was a 4.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 773,797 shares of company stock valued at $5,414,609. Insiders own 19.40% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Wednesday, December 11th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.